Physician profile
Jann Hara
NPI 1609842186
$6,689.50
in general payments reported to CMS, 2019-2025
10 companies · $822 in 2025
The $822 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $130 · 2021: $834 · 2022: $825 · 2023: $2,751 · 2024: $963 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920 · Travel and Lodging: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.90 |
| Travel and Lodging | $1,615.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,847.88 | 2019-2025 | Clareon Panoptix Pro, Precision7, Total30 |
| Bausch & Lomb Americas INC. | $1,703.39 | 2022-2025 | Infuse, Biotrue One Day, Infuse Svs |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $774.79 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $688.85 | 2019-2025 | Acuvue |
| Fujifilm Healthcare Americas Corporation | $204.55 | 2024 | Utaswako Afp-L3 |
| Genentech USA, INC. | $149.65 | 2022 | |
| Sight Sciences, INC. | $144.34 | 2023 | Omni Surgical System |
| Dompe US, INC. | $125.00 | 2025 | Oxervate |
| Coopervision INC. | $33.85 | 2023 | Misight Contact Lens |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jann Hara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.